FormWeb • daunorubicin liposomal-cytarabine liposomal

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Add Formweb to your mobile device

Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

daunorubicin liposomal-cytarabine liposomal

daunorubicin liposomal-cytarabine liposomal

Restricted Vyxeos --> restricted to oncology.

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Vyxeos	POWDER FOR INJECTION, INTRAVENOUS	44 mg-100 mg

Comments:

Vyxeos is restricted to oncology. Inpatient therapy recommended for induction phase, due to potential tumor lysis, strict monitoring, and need for transfusions, and in consolidation phase in patients that require hospitalization during that phase. Available for outpatient infusions during consolidation phase.

Reviewed: 24 July 2018 (Vyxeos)

Last updated: Jun. 29, 2022

Black Box Warning: Do Not Interchange with other Daunorubicin and/or Cytarabine Containing Products
HAZ-MED: Group 1 (daunorubicin liposomal)
HAZ-MED: Group 1 (cytarabine liposomal)
Chemotherapy:
Formulary, Not Routinely Stocked: Vyxeos --> 44 mg-100 mg

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.